Carlsmed 10-Q Details Q3 Revenue of $21.6M, 77.3% Gross Margin and $80.3M Liquidity
CARL sits 73% above its 52-week low of $8.5.
Summary
Carlsmed's Q3 10-Q confirms $21.6 million revenue (up 65%), a 77.3% gross margin and a widened $12.2 million net loss, backed by $80.3 million of liquidity and $15.6 million of debt.
Key Events · Earnings and Guidance · CARL
-
Q3 Revenue Jumps 65% to $21.6M
Revenue was $21.6 million for the third quarter of 2026 versus $13.1 million a year ago, driven by higher lumbar and cervical procedure volumes at roughly constant revenue per procedure.
-
Margins Improve, Net Loss Widens
Gross margin rose to 77.3% from 75.9%, but GAAP net loss widened to $12.2 million from $8.5 million as operating expenses climbed to $29.4 million from $19.0 million, including $2.4 million of executive transition costs.
-
Liquidity of $80.3M at Quarter End
Cash, cash equivalents, restricted cash, short-term investments and marketable securities totaled $80.3 million at September 30, 2026, against $15.6 million of term-loan principal and $34.4 million of remaining borrowing capacity.
-
Nine-Month Cash Burn of $29.0M
Net cash used in operating activities was $29.0 million for the nine months ended September 30, 2026, versus $23.7 million a year earlier, as working capital absorbed higher receivables and inventory.
Analysis · CARL · Industrial Applications And Services
The 10-Q fills in the numbers behind the same-day earnings release: revenue of $21.6 million (up 65%) carried a 77.3% gross margin, but the GAAP net loss widened to $12.2 million from $8.5 million as operating expenses grew faster than sales. The balance sheet is the key read — $80.3 million of cash and investments against $15.6 million of term-loan principal and $29.0 million of nine-month operating cash burn leaves roughly two-plus years of runway, so no near-term financing pressure despite the widening loss. The $250 million shelf filed in August remains unused headroom, not dilution already taken.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CARL was trading at $14.71 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $401.6M. The 52-week trading range was $8.50 to $17.23. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.